CA2471766C — Compositions for improving lipid metabolism
Assigned to NRL Pharma Inc · Expires 2011-01-11 · 15y expired
What this patent protects
It is intended to provide medicinal compositions which contain as the active ingredient at least one member selected from the group consisting of lactoferrin proteins including lactoferrin and conalbumin and enzymatically digested products of lactoferrin proteins including lactof…
USPTO Abstract
It is intended to provide medicinal compositions which contain as the active ingredient at least one member selected from the group consisting of lactoferrin proteins including lactoferrin and conalbumin and enzymatically digested products of lactoferrin proteins including lactoferricin and peptides of conalbumin corresponding to lactoferricin. These compositions are usable as lipid metabolism improving agents. Moreover, they are useful in treating lifestyle-related diseases such as hypercholesterolemia, hypertriglycedemia, low-density lipoprotein hypercholesterolemia, high-density lipoprotein hypocholesterolemia, obesity, fat liver, cholesterol cholelithiasis, severe obesity, hyperlipemia, hypertension, type II diabetes and so on. These composition can elevate basal metabolic rate.
Drugs covered by this patent
- Tradjenta (LINAGLIPTIN) · Boehringer Ingelheim
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.